Alleo and Ubiquigent Partner on AI-Driven Initiative to Accelerate DUB-Targeted Drug Discovery
Overview
Ubiquigent has announced a strategic collaboration with Alleo Labs. Alleo will combine its AI capabilities with Ubiquigent’s expertise in DUB-focused drug discovery.
Related to DUBs
DUBs as the drug target to harnessing them for the modulation or stabilisation of a given disease protein. These compounds are key to developing DUB inhibitors, DUB-targeting PROTACs, and DUB-Targeting Chimeras (DUBTACs).
DUB modulation remains a relatively untapped approach for targeting previously ‘undruggable’ drug targets.
Incorporation of AI Software
This partnership grants Ubiquigent exclusive access to Alleo's AI software, RubDUB, which will accelerate the search for new DUB-modulating compounds.
Alleo’s Work on Neuroscience Programmes
Meanwhile, Alleo will utilise Ubiquigent’s platforms and knowledge to advance its own precision neuroscience programmes, focusing on DUB modulation.
Both companies will also collaborate with third parties aiming to develop DUB-modulating therapeutics.
Related to Ubiquigent
Ubiquigent, a recognised leader in the DUB field, has an established record of developing DUB-targeting compounds and providing drug discovery services to partners.
The collaboration aims to accelerate the discovery and development of novel therapeutics.
Alleo Labs on Precision Medicine
Alleo Labs is focused on precision medicine for chronic neurological conditions.
Its lead programme, ALO-001, is an oral, brain-penetrating DUB inhibitor intended to combat neuroinflammation in Parkinson's and Alzheimer's diseases.
Current updates: - This programme is currently in preclinical development, with plans for first-in-human clinical trials.